Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$885.55 USD

885.55
1,972,736

-5.52 (-0.62%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer (PFE) Begins Clinical Study on COVID-19 Antiviral Pill

Pfizer (PFE) starts an early-stage U.S. study on an oral COVID-19 antiviral candidate.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $183.68, marking a -1.16% move from the previous day.

Kinjel Shah headshot

Pharma Stock Roundup: J&J, AZN COVID-19 Update, FDA Delays Decision on ABBV's sNDA

WHO gives EUL to J&J's (JNJ) COVID-19 vaccine. FDA pushes back review on AbbVie's (ABBV) sNDA

Lilly (LLY) Mirikizumab Meets Ulcerative Colitis Study Goal

Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.

Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation

Eli Lilly (LLY) announces detailed data on secondary endpoints of its mid-stage study evaluating its antibody candidate, donanemab, in patients with early symptomatic Alzheimer's disease.

The Zacks Analyst Blog Highlights: MGM Resorts, American Airlines, Blackstone Group, Extended Stay America and Eli Lilly

The Zacks Analyst Blog Highlights: MGM Resorts, American Airlines, Blackstone Group, Extended Stay America and Eli Lilly

Mark Vickery headshot

Markets Up on Strength in Resorts, Airline Bookings

As stimulus checks hit bank accounts across the nation and more Americans get their Covid-19 vaccine shots, pent-up demand in Travel & Leisure saw some big gains in select stocks today.

Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails

Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk

Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK

Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.

Lilly (LLY) Outperforms Industry Year to Date: Here's Why

Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.

Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint

Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.

The Zacks Analyst Blog Highlights: Eli Lilly, McDonald's, TOTAL, American Express and Southern Copper

The Zacks Analyst Blog Highlights: Eli Lilly, McDonald's, TOTAL, American Express and Southern Copper

Sheraz Mian headshot

Top Research Reports for Eli Lilly, McDonald's & TOTAL

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), McDonald's (MCD), and TOTAL SE (TOT).

Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study

Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.

Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod

CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.

Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.

Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Why Is Lilly (LLY) Down 2.5% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

Eli Lilly (LLY) closed at $204.89 in the latest trading session, marking a +0.52% move from the prior day.

Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track

Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

Benjamin Rains headshot

2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility

Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...